About Alpine Immune Sciences (NASDAQ:ALPN)
Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer. The company has a collaboration and licensing agreement with the Kite Pharma, Inc. for discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer. Alpine Immune Sciences, Inc. is headquartered in Seattle, Washington.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ALPN
CUSIPN/A
Phone206-788-4545
Debt
Debt-to-Equity Ratio0.05%
Current Ratio43.67%
Quick Ratio43.67%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.73 million
Price / Sales62.61
Cash FlowN/A
Price / CashN/A
Book Value$5.68 per share
Price / Book1.38
Profitability
EPS (Most Recent Fiscal Year)($1.20)
Net Income$-7,780,000.00
Net MarginsN/A
Return on Equity-30.50%
Return on Assets-28.15%
Miscellaneous
Employees38
Outstanding Shares13,850,000
Alpine Immune Sciences (NASDAQ:ALPN) Frequently Asked Questions
What is Alpine Immune Sciences' stock symbol?
Alpine Immune Sciences trades on the NASDAQ under the ticker symbol "ALPN."
How were Alpine Immune Sciences' earnings last quarter?
Alpine Immune Sciences (NASDAQ:ALPN) posted its quarterly earnings results on Wednesday, March, 28th. The biotechnology company reported ($0.33) EPS for the quarter, topping analysts' consensus estimates of ($0.37) by $0.04. The biotechnology company had revenue of $0.13 million for the quarter. View Alpine Immune Sciences' Earnings History.
What price target have analysts set for ALPN?
1 equities research analysts have issued 12 month price targets for Alpine Immune Sciences' shares. Their forecasts range from $17.00 to $17.00. On average, they expect Alpine Immune Sciences' share price to reach $17.00 in the next year. View Analyst Ratings for Alpine Immune Sciences.
Who are some of Alpine Immune Sciences' key competitors?
Some companies that are related to Alpine Immune Sciences include Calithera Biosciences (CALA), Verona Pharma (VRNA), Fortress Biotech (FBIO), Verastem (VSTM), Tocagen (TOCA), VBI Vaccines (VBIV), Menlo Therapeutics (MNLO), Ra Pharmaceuticals (RARX), POXEL (PXXLF), Xoma (XOMA), Marinus Pharmaceuticals (MRNS), Summit Therapeutics (SMMT), Nabriva Therapeutics (NBRV), Scpharmaceuticals (SCPH), Teligent (TLGT), Protagonist Therapeutics (PTGX), Zafgen (ZFGN) and Evolus (EOLS).
Who are Alpine Immune Sciences' key executives?
Alpine Immune Sciences' management team includes the folowing people:
- Dr. Mitchell H. Gold M.D., Exec. Chairman & CEO (Age 50)
- Dr. Jay R. Venkatesan M.D., Ph.D., Pres and Director (Age 46)
- Dr. Stanford Peng M.D., Ph.D., Exec. VP of R&D and Chief Medical Officer (Age 47)
- Mr. Paul Rickey, Sr. VP & CFO (Age 39)
- Mr. Ryan Swanson, Co-Founder
Has Alpine Immune Sciences been receiving favorable news coverage?
News articles about ALPN stock have trended somewhat positive recently, according to Accern. Accern identifies negative and positive news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Alpine Immune Sciences earned a media sentiment score of 0.16 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 44.73 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
How do I buy shares of Alpine Immune Sciences?
Shares of ALPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alpine Immune Sciences' stock price today?
One share of ALPN stock can currently be purchased for approximately $7.82.
How big of a company is Alpine Immune Sciences?
Alpine Immune Sciences has a market capitalization of $109.52 million and generates $1.73 million in revenue each year. The biotechnology company earns $-7,780,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Alpine Immune Sciences employs 38 workers across the globe.
How can I contact Alpine Immune Sciences?
Alpine Immune Sciences' mailing address is 201 Elliott Avenue West Suite 230, Seattle WA, 98119. The biotechnology company can be reached via phone at 206-788-4545 or via email at [email protected]
MarketBeat Community Rating for Alpine Immune Sciences (ALPN)
MarketBeat's community ratings are surveys of what our community members think about Alpine Immune Sciences and other stocks. Vote "Outperform" if you believe ALPN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALPN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Alpine Immune Sciences (NASDAQ:ALPN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for Alpine Immune Sciences in the last 12 months. Their average twelve-month price target is $17.00, suggesting that the stock has a possible upside of 117.39%. The high price target for ALPN is $17.00 and the low price target for ALPN is $17.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Hold |
| Consensus Rating Score: | 3.00 | 2.50 | 2.50 | 2.33 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $17.00 | $17.00 | $17.00 | $7.3125 |
| Price Target Upside: | 117.39% upside | 543.94% upside | 543.94% upside | 176.99% upside |
Alpine Immune Sciences (NASDAQ:ALPN) Consensus Price Target History
Alpine Immune Sciences (NASDAQ:ALPN) Analyst Ratings History
Show:
(Data available from 4/23/2016 forward)
Alpine Immune Sciences (NASDAQ:ALPN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Alpine Immune Sciences (NASDAQ ALPN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 9.80%
Institutional Ownership Percentage: 57.35%
Alpine Immune Sciences (NASDAQ ALPN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 6/20/2017 | Value Fund L P Biotechnology | Insider | Buy | 17,806 | $2.25 | $40,063.50 | |  |
| 6/7/2017 | Bvf Partners L P/Il | Major Shareholder | Buy | 36,900 | $2.28 | $84,132.00 | | |
| 6/7/2017 | Value Fund L P Biotechnology | Insider | Buy | 72,650 | $2.29 | $166,368.50 | | |
| 6/5/2017 | Bvf Partners L P/Il | Major Shareholder | Buy | 35,750 | $2.29 | $81,867.50 | | |
| 5/31/2017 | Value Fund L P Biotechnology | Insider | Buy | 47,000 | $2.27 | $106,690.00 | | |
| 5/19/2017 | Value Fund L P Biotechnology | Insider | Buy | 78,858 | $2.30 | $181,373.40 | | |
| 5/11/2017 | Value Fund L P Biotechnology | Insider | Buy | 109,034 | $2.32 | $252,958.88 | | |
| 5/9/2017 | Robert E Conway | Director | Buy | 5,000 | $2.34 | $11,700.00 | 45,000 | |
| 5/8/2017 | Robert E Conway | Director | Buy | 15,000 | $2.28 | $34,200.00 | 60,000 | |
| 5/5/2017 | Janice Troha | EVP | Buy | 10,000 | $2.34 | $23,400.00 | 10,000 | |
| 5/5/2017 | Robert E Conway | Director | Buy | 20,000 | $2.30 | $46,000.00 | 40,000 | |
| 5/4/2017 | Robert E Conway | Director | Buy | 10,000 | $2.26 | $22,600.00 | 20,000 | |
| 1/4/2017 | David Malcom Rodman | EVP | Sell | 6,687 | $2.27 | $15,179.49 | 18,055 | |
| 12/2/2016 | R Michael Carruthers | EVP | Buy | 24,000 | $2.09 | $50,160.00 | 24,000 | |
| 10/4/2016 | David Malcom Rodman | EVP | Sell | 5,820 | $7.96 | $46,327.20 | 18,056 | |
| 7/5/2016 | David Malcom Rodman | CMO | Sell | 5,950 | $4.66 | $27,727.00 | 18,055 | |
| 6/16/2016 | Jon Congleton | CEO | Buy | 5,000 | $3.87 | $19,350.00 | 20,000 | |
| 3/24/2016 | Jon Congleton | CEO | Buy | 5,000 | $4.22 | $21,100.00 | 15,000 | |
| 3/22/2016 | Jon Congleton | CEO | Buy | 5,000 | $4.38 | $21,900.00 | 10,000 | |
| 12/11/2015 | Jon Congleton | CEO | Buy | 5,000 | $8.10 | $40,500.00 | 5,000 | |
| 12/9/2015 | Robert E Conway | Director | Buy | 10,000 | $8.10 | $81,000.00 | 10,000 | |
| 6/23/2015 | James E Flynn | Insider | Buy | 250,000 | $14.00 | $3,500,000.00 | | |
| 6/22/2015 | Bay Master Investors (C Hawkes | Major Shareholder | Buy | 17,200 | $14.69 | $252,668.00 | | |
| 6/18/2015 | Bay Master Investors (C Hawkes | Major Shareholder | Buy | 20,400 | $14.47 | $295,188.00 | | |
| 6/17/2015 | Global Healthcare Mas Jennison | Major Shareholder | Buy | 26,149 | $14.00 | $366,086.00 | | |
(Data available from 1/1/2013 forward)
Alpine Immune Sciences (NASDAQ ALPN) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Alpine Immune Sciences (ALPN) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 20 at 9:56 AM |
| ValuEngine Upgrades Alpine Immune Sciences (ALPN) to Hold
www.americanbankingnews.com - April 15 at 3:27 PM |
| Alpine Immune Sciences (ALPN) Downgraded to "Sell" at ValuEngine
www.americanbankingnews.com - April 14 at 1:29 PM |
| Alpine Immune Sciences (ALPN) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - April 7 at 3:18 PM |
| Alpine Immune Sciences (ALPN) Announces Earnings Results
www.americanbankingnews.com - March 29 at 7:38 AM |
 | BRIEF-Alpine Immune Sciences Provides Corporate Update And Reports Full Year 2017 Financial Results
www.reuters.com - March 28 at 9:44 AM |
 | Alpine Immune Sciences Announces Poster Presentation at the 2018 AACR Annual Meeting
finance.yahoo.com - March 22 at 9:44 AM |
| -$0.44 EPS Expected for Alpine Immune Sciences, Inc. (ALPN) This Quarter
www.americanbankingnews.com - March 18 at 11:08 PM |
| Alpine Immune Sciences to Present at Cowen 38th Annual Health Care Conference
finance.yahoo.com - February 27 at 5:02 PM |
| Alpine Immune Sciences, Inc. (ALPN) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - February 24 at 3:38 PM |
| Zacks: Brokerages Anticipate Alpine Immune Sciences, Inc. (ALPN) Will Announce Earnings of -$0.44 Per Share
www.americanbankingnews.com - February 13 at 5:24 AM |
| Alpine Immune Sciences (ALPN) Downgraded by Zacks Investment Research
www.americanbankingnews.com - January 16 at 4:36 PM |
| Alpine Immune Sciences (ALPN) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - January 15 at 5:50 PM |
| Alpine Immune Sciences (ALPN) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - January 4 at 5:52 PM |
| Alpine Immune Sciences (ALPN) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - January 2 at 6:46 PM |
| ValuEngine Upgrades Alpine Immune Sciences (ALPN) to Sell
www.americanbankingnews.com - December 31 at 12:46 AM |
| Alpine Immune Sciences (ALPN) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - December 26 at 5:29 PM |
| Zacks: Analysts Expect Alpine Immune Sciences, Inc. (ALPN) to Post -$0.44 EPS
www.americanbankingnews.com - December 24 at 7:16 PM |
| Alpine Immune Sciences Announces Preclinical Data from ALPN-101 Program Demonstrating Efficacy in Humanized Model of Graft Versus Host Disease
finance.yahoo.com - December 19 at 8:55 AM |
| Alpine Immune Sciences, Inc. (ALPN) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - December 11 at 6:28 PM |
| Alpine Immune Sciences Announces Preclinical Data Showing Novel Immuno-Oncology Costimulatory Molecules Generated from vIgD Platform Fused with Trastuzumab Enhanced Immune Responses Against HER2-Positive Tumor Cells
finance.yahoo.com - December 6 at 9:05 AM |
| Nivalis Therapeutics, Inc. (ALPN) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - November 16 at 3:50 PM |
| Nivalis Therapeutics, Inc. (ALPN) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - November 15 at 5:06 PM |
| Alpine Immune Sciences Reports Corporate Update and Third Quarter 2017 Financial Results
finance.yahoo.com - November 14 at 2:50 AM |
| Alpine Immune Sciences Presents Preclinical Data on Novel Immuno-Oncology Molecules at the Society for Immunotherapy of Cancer’s 32nd Annual Meeting
finance.yahoo.com - November 10 at 2:28 PM |
| Nivalis Therapeutics (ALPN) & The Competition Critical Review
www.americanbankingnews.com - November 7 at 5:34 AM |
| Alpine Immune Sciences Presents ALPN-101 Program Data Demonstrating Potent Preclinical Activity in Arthritis and Inflammation
finance.yahoo.com - November 6 at 4:34 PM |
| Alpine Immune Sciences to Present at Two Upcoming Investor Conferences in November
finance.yahoo.com - November 1 at 4:12 PM |
| Zacks Investment Research Lowers Nivalis Therapeutics, Inc. (ALPN) to Strong Sell
www.americanbankingnews.com - October 26 at 7:24 PM |
| Alpine Immune Sciences and Kite Extend Research Term of Collaboration to Create Next-Generation CAR-T and TCRs
finance.yahoo.com - October 23 at 4:51 PM |
| Nivalis Therapeutics, Inc. (ALPN) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - October 22 at 4:44 PM |
| Alpine Immune Sciences Announces Upcoming Scientific Presentations
finance.yahoo.com - October 16 at 4:35 PM |
 | Impel NeuroPharma names CEO
www.bizjournals.com - October 6 at 4:21 AM |
| Nivalis Therapeutics, Inc. (ALPN) Raised to Buy at Stifel Nicolaus
www.americanbankingnews.com - September 22 at 7:44 AM |
| Alpine Immune Sciences Announces Poster Presentation at 2017 ACR/ARHP Annual Meeting
finance.yahoo.com - September 20 at 3:41 PM |
| Alpine Immune Sciences to Present at Ladenburg Thalmann 2017 Healthcare Conference
finance.yahoo.com - September 13 at 4:51 PM |
| Nivalis Therapeutics, Inc. (ALPN) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - September 2 at 7:16 PM |
| -$0.28 EPS Expected for Nivalis Therapeutics, Inc. (ALPN) This Quarter
www.americanbankingnews.com - August 15 at 6:06 PM |
| Strength Seen in FibroGen (FGEN): Stock Soars 48.2%
finance.yahoo.com - August 9 at 3:55 PM |
| Nivalis Therapeutics, Inc. (NASDAQ:ALPN) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - August 8 at 6:44 PM |
| Corcept (CORT) Looks Good: Stock Moves Up 8.8% in Session
finance.yahoo.com - August 3 at 4:45 PM |
| Alpine Immune Sciences, Inc. (ALPN) Now Covered by Analysts at Ladenburg Thalmann Financial Services
www.americanbankingnews.com - July 27 at 9:24 AM |
Alpine Immune Sciences (NASDAQ:ALPN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Alpine Immune Sciences (NASDAQ:ALPN) Income Statement, Balance Sheet and Cash Flow Statement
Alpine Immune Sciences (NASDAQ ALPN) Stock Chart for Monday, April, 23, 2018
Loading chart…
